---
source_path: R2505L-PDF-ENG.md
pages: n/a-n/a
chunk_id: ce2f08436adc89c02d45f8c7f7e90f6d5519e25d
title: R2505L-PDF-ENG
---
# Joseph Ernst/The Sideline Collective

On November 10, 2022, a tweet sent shockwaves through the

pharmaceutical industry. A veriﬁed Twitter (now X) account claiming to

represent Eli Lilly, one of the world’s pharmaceutical giants, announced

that the drugmaker would begin providing insulin free of charge.

Within hours, the post went viral, garnering over 11,000 likes and

1,500 retweets. The impact was immediate: Online searches for Eli Lilly

surged by more than 80% in just one day. For millions of people reliant

Copyright © 2025 Harvard Business School Publishing. All rights reserved.

1

This document is authorized for use only by Matt O'Donnell (matthew.od11@gmail.com). Copying or posting is an infringement of copyright. Please contact customerservice@harvardbusiness.org or 800-988-0886 for additional copies.
